JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B

Accepted manuscript available online (unedited version)

Efficacy and safety of toludesvenlafaxine vs venlafaxine in depression: a multicenter, open-label, randomized controlled trial

Author(s): Jinyu ZHANG^1, ^2, ³; Xiaonan GUO^2, ³; Yiheng CUI^1, ^2, ³; Peng ZHANG⁸; Yunrong LU⁹; Ning WEI^2, ^3, ^4, ^5, ^6, ⁷; Shaohua HU^1, ^2, ^3, ^4, ^5, ^6, ⁷
Affiliation(s): ¹Wenzhou Medical University, Wenzhou 325035, China ²Department of Psychiatry, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China ³Nanhu Brain-computer Interface Institute, Hangzhou 311121, China ⁴MOE Frontier Science Center for Brain Science and Brain-Machine Integration, Zhejiang University School of Medicine, Hangzhou 310003, China ⁵Brain Research Institute of Zhejiang University, Hangzhou 310003, China ⁶The State Key Lab of Brain-Machine Intelligence, Zhejiang University, Hangzhou 310058, China ⁷Zhejiang Engineering Center for Mathematical Mental Health, Hangzhou 311121 China ⁸Department of Psychiatry, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou 311200, China ⁹Department of Psychiatry, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
Corresponding email(s): Peng ZHANG, kokozippo@163.com Yunrong LU, 2201005@zju.edu.cn Ning WEI, nwei2011@163.com Shaohua HU, dorhushaohua@zju.edu.cn
Key Words: Toludesvenlafaxine; Venlafaxine; Major depressive disorder; Antidepressants

Share this article to： More <<< Previous Paper \|Next Paper >>>

Jinyu ZHANG^1,^2,³; Xiaonan GUO^2,³; Yiheng CUI^1,^2,³; Peng ZHANG⁸; Yunrong LU⁹; Ning WEI^2,^3,^4,^5,^6,⁷; Shaohua HU^1,^2,^3,^4,^5,^6,⁷. Efficacy and safety of toludesvenlafaxine vs venlafaxine in depression: a multicenter, open-label, randomized controlled trial[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2500560

@article{title="Efficacy and safety of toludesvenlafaxine vs venlafaxine in depression: a multicenter, open-label, randomized controlled trial",
author="Jinyu ZHANG^1,^2,³; Xiaonan GUO^2,³; Yiheng CUI^1,^2,³; Peng ZHANG⁸; Yunrong LU⁹; Ning WEI^2,^3,^4,^5,^6,⁷; Shaohua HU^1,^2,^3,^4,^5,^6,⁷",
journal="Journal of Zhejiang University Science B",
year="in press",
publisher="Zhejiang University Press & Springer",
doi="https://doi.org/10.1631/jzus.B2500560"
}

%0 Journal Article
%T Efficacy and safety of toludesvenlafaxine vs venlafaxine in depression: a multicenter, open-label, randomized controlled trial
%A Jinyu ZHANG^1
%A^2
%A³
%A Xiaonan GUO^2
%A³
%A Yiheng CUI^1
%A^2
%A³
%A Peng ZHANG⁸
%A Yunrong LU⁹
%A Ning WEI^2
%A^3
%A^4
%A^5
%A^6
%A⁷
%A Shaohua HU^1
%A^2
%A^3
%A^4
%A^5
%A^6
%A⁷
%J Journal of Zhejiang University SCIENCE B
%P
%@ 1673-1581
%D in press
%I Zhejiang University Press & Springer
doi="https://doi.org/10.1631/jzus.B2500560"

TY - JOUR
T1 - Efficacy and safety of toludesvenlafaxine vs venlafaxine in depression: a multicenter, open-label, randomized controlled trial
A1 - Jinyu ZHANG^{1
A1 -}^{2
A1 -}³
A1 - Xiaonan GUO^{2
A1 -}³
A1 - Yiheng CUI^{1
A1 -}^{2
A1 -}³
A1 - Peng ZHANG⁸
A1 - Yunrong LU⁹
A1 - Ning WEI^{2
A1 -}^{3
A1 -}^{4
A1 -}^{5
A1 -}^{6
A1 -}⁷
A1 - Shaohua HU^{1
A1 -}^{2
A1 -}^{3
A1 -}^{4
A1 -}^{5
A1 -}^{6
A1 -}⁷
J0 - Journal of Zhejiang University Science B
SP -
EP -
%@ 1673-1581
Y1 - in press
PB - Zhejiang University Press & Springer
ER -
doi="https://doi.org/10.1631/jzus.B2500560"

Abstract
Chinese Summary
Academic Network
Reviewer Comment

Abstract: Toludesvenlafaxine, a novel serotonin-norepinephrine-dopamine reuptake inhibitor, has shown promise in treating depression, yet direct comparisons with venlafaxine, a standard serotonin-norepinephrine reuptake inhibitor, remain limited, especially in the anhedonia facet. To address this gap, an 8-week multicenter, open-label, randomized controlled trial was conducted to compare toludesvenlafaxine with venlafaxine as monotherapies for major depressive disorder (MDD). Assessments were performed at baseline and weeks 2, 4 and 8, including evaluations of anhedonia (Snaith-Hamilton Pleasure Scale (SHAPS) and Dimensional Anhedonia Rating Scale (DARS)), general depressive symptoms (Montgomery-?sberg Depression Rating Scale (MADRS), 17-item Hamilton Depression Rating Scale (HAMD-17), and Self-Rating Depression Scale (SDS)), quality of life (Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)), as well as safety (Treatment Emergent Symptom Scale (TESS)) and sexual function (Arizona Sexual Experience Scale (ASEX)). The results showed that, compared with venlafaxine, toludesvenlafaxine had an earlier onset of action at week 2 in improving MADRS and HAMD-17 scores, along with alleviating anhedonia and suicidal ideation. At week 8, however, the SHAPS scores were comparable between the two groups, indicating their similar efficacy in treating anhedonia. In terms of safety, toludesvenlafaxine exhibited significantly lower levels of triglycerides and total bilirubin, while other indices demonstrated no significant difference. Overall, both drugs showed comparable efficacy and safety profiles for MDD over the 8-week treatment period, with toludesvenlafaxine potentially acting more rapidly.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

Open peer comments: Debate/Discuss/Question/Opinion

<1>

- Go to

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference